INTRODUCTION

Lung cancer remains the most common cause of mortality from malignant disease in the world for several decades, and it has been the most common cancer in China.\(^1\) It is estimated that there are 1.8 million new cases in 2012, 58% of them occur in the less developed countries.\(^2\) Non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer cases, and has a overall five-year survival rate of less than 15%.\(^2,3\) Most of the NSCLC patients show locally advanced or metastatic disease when diagnosed.\(^2\) Platinum agents have been used as the first-line chemotherapeutic regimens to improve the clinical outcome of advanced NSCLC.\(^3\) Despite advances in diagnostics, surgery and chemotherapy, 70% of NSCLC patients still show metastatic disease after receiving chemotherapy.\(^4\) Moreover, even patients with similar clinical characteristics present different response to chemotherapy, which shows that some molecular biomarkers have a role in altering the efficacy of chemotherapy for advanced NSCLC patients. Therefore, detection of molecular...
markers could help design individualized chemotherapy to improve the survival of advanced NSCLC.

Previous study reported that bulky DNA adducts by cisplatin or carboplatin are mainly repaired by nucleotide excision repair pathway. The DNA repair mechanism can allow cancer cell to repair the DNA damages caused by platinum compounds, and it can influence the anticancer effect of these agents. Excision repair cross complementing 1 (ERCC1) and breast cancer susceptibility gene 1 (BRCA1) are two key factors involved in nuclear excision repair, and increased clinical data have showed that expression. Ribonucleotide reductase subunit M1(RRM1) and Ribonucleotide reductase subunit M2(RRM2) are encoded by different genes on separate chromosomes and their mRNAs are differentially expressed through the cell cycle, and over-expression of RRM1 and RRM2 is correlated with resistance to chemotherapy.

Previous studies have reported the association between ERCC1, BRCA1, RRM1 and RRM2 and NSCLC prognosis. However, the results are inconsistent. Therefore, we conducted this prospective study to investigate the role of mRNA expression quantities of ERCC1, BRCA1, RRM1 and RRM2 in NSCLC patients, and investigate their association with response to chemotherapy and clinical outcome of advanced NSCLC.

METHODS

Subjects: 236 eligible patients who were diagnosed as advanced stage NSCLC were enrolled at the First Affiliated Hospital of Xinxiang Medical University between January 2009 and January 2010. Finally, 208 patients agreed to participate into our study, with participation rate of 88.1%. Excluded criteria were patients who previously received radiotherapy or chemotherapy, and those who had symptomatic brain metastases, spinal cord compression and uncontrolled massive pleural effusion. Informed consent was obtained from all patients before conducting the study. All the patients were followed up until January 2012. The study protocol was approved by the ethics committee of the First Affiliated Hospital of Xinxiang Medical University.

Study design: All patients were treated with platinum-based doublets chemotherapy. The treatment regimens included 25 mg/m² vinorelbine on day one and day eight, or 1000mg/m² gemcitabine plus 75 mg/m² cisplatin or carboplatin on day one. The chemotherapy treatment was conducted every three weeks, and then the toxicities were evaluated after chemotherapy. The chemotherapy treatment was conducted for a maximum of six cycles. When patients showed grade three or four drug-related toxicities, the dose of cytotoxic agents were immediately reduced by 25%. The response to platinum-based doublets chemotherapy was assessed by the WHO criteria.

Complete remission (CR) and partial remission (PR) were defined as responsive and stable disease (SD) and progressive disease (PD) were defined as non-responsive. Overall survival (OS) was calculated from the time of diagnosis to the time of death or the end of follow-up.

RNA isolation and cDNA quantification: 5 mlL whole blood samples were collected from each patient, and stored at −20°C until use. For genotype determination, extraction of RNA from a peripheral blood sample was conducted by an EZNA Blood RNA Mini Kit (Omega, Berkeley, CA, US). A fluorescence-based and real-time detection method was used to determine the relative cDNA quantification for ERCC1, BRCA1, RRM1 and RRM2, and β-actin was used as the reference gene. When comparing the threshold cycle with the standard curve (β-actin amount), the relative amount of cRNA of ERCC1, BRCA1, RRM1 and RRM2 was determined. Primers and probes of the ERCC1, BRCA1, RRM1 and RRM2 for polymerase chain reaction (PCR) amplification were designed using Sequenom Assay Design 3.1 software (Sequenom).The PCR reaction was started at 95°C for 10 min to activate Taq polymerase, followed by 45 cycles of denaturation at 95°C for 15 s, and annealing at 60°C for 60s.

Statistical analysis: Mean ± standard deviation (SD) was used to express the continuous variables, whereas frequencies and percentages were used to express the categorical variables. Multivariate logistic regression analysis was conducted to assess the association between ERCC1, BRCA1, RRM1 and RRM2 mRNA expression and response to chemotherapy, with adjusted odd ratios and their 95% confidence intervals (95%CI). The survival distribution was plotted by Kaplan-Meier methods and compared by log-rank test. Cox regression analysis was conducted to assess the association between ERCC1, BRCA1, RRM1 and RRM2 mRNA expression and overall survival, with hazard ratios (HR) and 95% confidence interval (95%CI). Statistical analyses were performed using the SPSS® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows. Two-tailed with a P-value <0.05 was considered as statistical significant.
RESULTS

Patients: Characteristics of patients are summarized in Table I. The median age of the enrolled patients was 64.1 (25.3-86.1) years. Among these 208 patients, 117 (56.3%) were above the age of 60 years old, 158 (76.2%) were men, 69 (33.2%) were current or former smokers, 157 (75.5%) were at stage IV diseases and 190 (91.6%) were squamous and adenocarcinoma non-small cell lung cancer. After performing platinum-based doublets chemotherapy for these NSCLC patients, 87 (41.7%) patients showed CR and PR to chemotherapy, and 121 (58.3%) achieved SD and PD to chemotherapy.

The standardized mRNA quantification amount of ERCC1, BRCA1, RRM1 and RRM2 was assessed by comparing the target amount of β-action amount. The expression of ERCC1, BRCA1, RRM1 and RRM2 was classified into high and low expression according to median expression level. The median expression levels of ERCC1, BRCA1, RRM1 and RRM2 were 0.67±0.17, 0.095±0.012, 0.24±0.17 and 2.45±0.32, respectively (Table II). Our study found that the low ERCC1 and Low BRCA1 mRNA expression was more likely to be response to chemotherapy when compared with high expression, with the ORs (95% CI) of 1.82 (1.01-3.20) and 2.53 (1.38-4.64), respectively. However, we did not find the low level of RRM1 (OR=1.43, 95% CI=0.79-2.57) and RRM2 (OR=1.13, 95% CI=0.63-1.13) mRNA expression has a role on the response to platinum-based chemotherapy.

The median overall survival of enrolled patients was 17.9±7.5 months. We found that low expression of ERCC1 and BRCA1 mRNA had significantly longer overall survival time when compared with high expression of ERCC1 and BRCA1 mRNA (Table III). Multivariate Cox regression analysis indicated that patients with low expression of ERCC1 and BRCA1 attained 0.43 (OR=0.43, 95% CI=0.27-0.89) and 0.37 (OR=0.37, 95% CI=0.22-0.66) fold risk of death from NSCLC (Fig 1 and Fig 2). However, no association was found between RMM1 and RRM2 mRNA expression and prognosis of NSCLC.

DISCUSSION

Our study found an inverse correlation between ERCC1 and BRCA1 mRNA expression and response to platinum-based chemotherapy and clinical
outcome of advanced NSCLC patients. Our study suggests expression of ERCC1 and BRCA1 mRNA could be helpful in predicting the clinical outcome of NSCLC and understand the pathogenesis of chemotherapy for NSCLC. Recently, several studies reported the association between ERCC1, BRCA1, RRM1 and RRM2 mRNA expression and clinical outcome of NSCLC.\(^3,8-13\) Zhang et al. reported that RRM1 and ERCC1 mRNA expression in tumor tissue could be predictive and prognostic biomarkers in advanced NSCLC receiving platinum-based chemotherapy.\(^3\) Boukouvinas et al. reported that mRNA expression of BRCA1, RRM1 and RRM2 could be used to design individualized chemotherapy for NSCLC patients.\(^9\) Vassalou et al. reported that ERCC1 protein expression in tumor cell could influence the response rate to chemotherapy and clinical outcome of advanced NSCLC patients.\(^12\) However, the results are inconsistent. Therefore, we investigated the role of mRNA expression quantities of ERCC1, BRCA1, RRM1 and RRM2 in response to chemotherapy and clinical outcome of NSCLC patients.

ERCC1 is one of the key factors involved in nuclear excision repair and encodes the 5′endonuclease of the NER complex. It is reported that high expression of ERCC1 is corrected with resistance to cisplatin, which is involved in correcting the excision repair deficiency of the NER pathway.\(^15\) Previous studies reported that mRNA expression of ERCC1 was associated with response to chemotherapy and clinical outcome of head and neck cancer, colorectal cancer, gastric cancer and breast cancer.\(^16-19\) For patients with NSCLC, mRNA expression of ERCC1 might play an important role in the prognosis of NSCLC patients treated with chemotherapy.\(^3,8,11-13\) One study conducted in China indicated that low expression of ERCC1 in peripheral blood or tumor tissue was associated with better response to chemotherapy longer median survival and longer progression-free survival.\(^3\) Another study conducted also conducted in China indicated that high ERCC1 protein expression was associated with clinical outcome of NSCLC patients treated with platinum-based chemotherapy.\(^3\) The previous two studies are in line with our findings. However, another study reported that ERCC1 expression was not prognostic of tumor recurrence and overall survival in patients with advanced NSCLC.\(^12,13\) The inconsistency of these findings could be explained by differences in ethnicities, number of included cases and study design. Therefore, further studies with different populations are greatly needed to confirm the finding of our study.

Table-II: ERCC1, BRCA1, RRM1 and RRM2 mRNA expression and response to chemotherapy.

| Expression level   | Total expression quantities | Responders | Non-responders | p value | OR(95%CI) |
|--------------------|----------------------------|------------|----------------|---------|-----------|
|                    | N=87 %                     | N=121 %    |                |         |           |
| High ERCC1         | 0.67±0.17                 | 36 41.4    | 68 56.2        | -       | 1.0(Ref.) |
| Low ERCC1          | 0.095±0.012               | 51 58.6    | 53 43.8        | 0.04    | 1.82(1.01-3.20) |
| High BRCA1         | 0.24±0.17                 | 40 46.0    | 64 52.9        | -       | 1.0(Ref.) |
| Low BRCA1          | 0.095±0.012               | 55 63.2    | 49 40.5        | 0.02    | 2.53(1.38-4.64) |
| High RRM1          | 0.24±0.17                 | 49 56.3    | 55 45.5        | 0.21    | 1.43(0.79-2.57) |
| Low RRM1           | 2.45±0.32                 | 42 48.3    | 62 51.2        | -       | 1.0(Ref.) |
| Low RRM2           | 2.45±0.32                 | 45 51.7    | 59 48.8        | 0.67    | 1.13(0.63-1.13) |

Table-III: ERCC1, BRCA1, RRM1 and RRM2 mRNA expression and overall survival of advanced NSCLC

| Gene           | Death N=113 | %    | Alive N=95 | %    | Overall Survival Median (month) | Log-rank | OS HR(95%CI) | P value |
|----------------|-------------|------|------------|------|---------------------------------|----------|-------------|---------|
| High ERCC1     | 66          | 58.4 | 38         | 40.0 | 16.05                           | -        | 1.0(Ref.)  | 0.008   |
| Low ERCC1      | 47          | 41.6 | 57         | 60.0 | 21.32                           | 0.02     | 0.43(0.27-0.89) | <0.001  |
| High BRCA1     | 70          | 61.9 | 34         | 35.8 | 14.75                           | -        | 1.0(Ref.)  |         |
| Low BRCA1      | 43          | 38.1 | 61         | 64.2 | 22.61                           | 0.004    | 0.37(0.22-0.66) | <0.001  |
| High RRM1      | 62          | 54.9 | 42         | 44.2 | 17.25                           | -        | 1.0(Ref.)  |         |
| Low RRM1       | 51          | 45.1 | 53         | 55.8 | 19.65                           | 0.17     | 0.65(0.39-1.23) | 0.58    |
| High RRM2      | 58          | 51.3 | 46         | 48.4 | 18.6                            | -        | 1.0(Ref.)  |         |
| Low RRM2       | 55          | 48.7 | 49         | 51.6 | 20.7                            | 0.75     | 0.89(0.50-1.59) | 0.68    |
pivotal.\textsuperscript{20,21} Previous meta-analysis reported that the individuals with low or negative expression of BRCA1 were associated with longer OS and better objective response rate\textsuperscript{20} which is consistent with our study.

There are some limitations in our study. First, these advanced NSCLC patients were selected from one place, which may not better represent NSCLC patients in other populations. Second, the sample size of this study is relative small, which would reduce the statistical power to find the difference between groups. The relatively small sample size may be the reason that no association was found between RRM1 and RRM2 mRNA expression and clinical outcome of NSCLC patients. Therefore, further large sample size and well designed studies are warranted.

In conclusion, our results indicate that mRNA expression of ERCC1 and BRCA1 could influence the efficacy of chemotherapy and clinical outcome of advanced NSCLC patients. Therefore, ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.

**ACKNOWLEDGEMENT**

We thank the helps from the staffs from First Affiliated Hospital of Xinxiang Medical University, and funding from Science and Technology Department of Henan Province (No.62303130).

**REFERENCES**

1. International Agency for Research on Cancer. Lung cancer estimated incidence, Mortality and Prevalence Worldwide in 2012. 2012. http://globocan.iarc.fr/factsheet.asp. Access on: 2014-2-1.
2. William VN Jr, Lin HY, Lee JJ, Lippman SM. Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data. Chest. 2009;136:201-209. DOI: 10.1378/chest.08-2686.
3. Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, et al. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;69(5):1277-1287. DOI: 10.1007/s00280-012-1834-x.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. DOI: 10.3322/caac.20073.
5. Matakidou A, el Galta R, Webb EL. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16:2333–2340. DOI: 10.1093/hmg/ddm190.
6. Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, et al. Assessment of XPD Lys751Gln and XRCC1 17-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2011;71(1):110-115. DOI: 10.1016/j.lungcan.2010.11.004.
7. Yuanning L, Lineng Z, Baorong S, Junjie P, Sanjun C. BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer. 2013;13:103. DOI: 10.1186/1475-282X-13-103.
8. Bergert E, Levallet G, Campbell K, Dubois F, Lechapt E, Zaleman G. Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev. 2013;22(130):565-576. DOI: 10.1183/09059181.00071313.
9. Boukouvinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutouphoulos A, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One. 2008;3(11):e3695. DOI: 10.1371/journal.pone.0003695.
10. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12(10):807-817.
11. Yan D, Wei P, An G, Chen W. Prognostic potential of ERCC1 protein expression & clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg. 2013;8:149. DOI: 10.1186/1757-1053-8-149.
12. Sodja E, Kneze L, Kern I, Ovčariček T, Sadikov A, Cufer T. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer. 2012;48(18):3378-3385. DOI: 10.1016/j.ejca.2012.06.011.
13. Han Y, Wang XB, Xiao N, Liu ZD. mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TMY3 and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev. 2013;14(5):2987-2990. DOI: 10.7314/APJCP.2013.14.5.2987.
14. Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saito N. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003;94(11):1015-1020. DOI: 10.1111/j.1349-7006.2003.tb01394.x.
15. van Duin M, de Wit J, Odijk H, Westerveld A, Yasaki A, Koken MH, Hoeijmakers JH, Bootsma D. Molecular characterization of the human excision repair gene ERCC1-1 DNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell. 1986;44(6):913-923.
16. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez F, Parvathenani U, Chai X, Sampath S, Martins RG. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013;109(9):2096-2105. DOI: 10.1038/bjc.2013.576.
17. Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, et al. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol. 2013;107(8):457-464. DOI: 10.1002/jso.23422.
18. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett. 2013;5(3):935-942. DOI: 10.3892/ol.2012.1096.
19. Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, et al. Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 2013;209(6):331-336. DOI: 10.1016/j.prp.2013.02.009.
20. Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predictive clinical outcome in platinum- and taxol-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Cancer Res. 2013;32:15. DOI: 10.1186/1471-2407-32-15.
21. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Genet. 2007;8(11):700-712. DOI: 10.1038/nrm2831.

Authors Contributions: FXJ & LPF designed and performed the study, did statistical analysis & editing of manuscript.

LD, ZL, WWL, QXG & FH did data collection and manuscript writing.

Authors:

1. Feng Xian-jun, Department of Respiratory Medicine.
2. Qin Xiu-guang, Department of Thoracic Surgery.
3. Zang Li, Combine Traditional Chinese and Western Medicine Dept., Xinxiang Medical University, Xinxiang, China.
4. Feng Hui, Combine Traditional Chinese and Western Medicine Dept., Xinxiang Medical University, Xinxiang, China.
5. Wang Wan-ling, Department of Hematology, Xinxiang Medical University, Xinxiang, China.
6. Liu Dong, Department of Dermatology, Xinxiang Medical University, Xinxiang, China.
7. Li Ping-fa, Department of Hematology, Xinxiang Medical University, Xinxiang, China.
8. Yan D, Department of Thoracic Surgery, Xinxiang Medical University, Xinxiang, China.
9. Xue Zhi-feng, Department of Respiratory Medicine, Xinxiang Medical University, Xinxiang, China.
10. Fujita H, Department of Thoracic Surgery, Xinxiang Medical University, Xinxiang, China.
11. Feng Xuan-jun, Department of Respiratory Medicine, Xinxiang Medical University, Xinxiang, China.
12. Zhang Li, Department of Dermatology, Xinxiang Medical University, Xinxiang, China.
13. Yan D, Department of Hematology, Xinxiang Medical University, Xinxiang, China.
14. Zeng Li, Department of Respiratory Medicine, Xinxiang Medical University, Xinxiang, China.
15. Liu Dong, Department of Dermatology, Xinxiang Medical University, Xinxiang, China.
16. Feng Xian-jun, Department of Respiratory Medicine, Xinxiang Medical University, Xinxiang, China.